Research Priorities

Gates MRI focuses on programs aimed at reducing the burden of tuberculosis (TB) and malaria in low-and-middle-income countries (LMICs). LMICs, a term originally defined by the World Bank 1, are often the most impacted by such diseases.

The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities to address substantial global health concerns, for which investment incentives are limited.

References

Pipeline Overview

We have a total of 9 assets across four business programs, which include three development programs in pre-clinical stage, four programs in clinical phase 1, one in clinical phase 2, and one in clinical phase 3.

Expanded Access Policy

To support our mission, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our interventions broadly available as quickly as possible, and we are privileged to collaborate with our development partners, clinical trial investigators, community advisory boards, and with participants in our clinical trials supporting our development programs. The Gates MRI is focused on evaluating investigational products in clinical trials and does not have an expanded access program for investigational products. Information about Gates MRI-sponsored clinical trials can be found on our website and on clinical trial registries, e.g., https://clinicaltrials.gov/ under trials listed for Gates Medical Research Institute.

Research Priorities

Learn more about our research programs at the Gates MRI by clicking on the icons.

Malaria

Caused by Plasmodium parasites, spread through the bite of infected Anopheles mosquitoes

Tuberculosis

An infectious disease caused by Mycobacterium tuberculosis (Mtb) bacteria, spread by bacteria expelled into the air